Amicus Therapeutics (FOLD) |
|
10.66 -0.51 (-4.57%)
|
03-03 17:02 |
|
Open: |
11.205 |
Pre. Close: |
11.17 |
|
High:
|
11.28 |
Low:
|
10.64 |
|
Volume:
|
4,541,571 |
Market Cap:
|
2,794M |
|
|
|
|
Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of therapies to treat a range of rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting Phase 3 (ATB200-03) clinical study of AT-GAA for Pompe disease. The company has collaboration and license agreements with Nationwide Children's Hospital and University of Pennsylvania. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.304 - 11.372 |
11.372 - 11.422 |
|
Low:
|
10.484 - 10.57 |
10.57 - 10.635 |
|
Close:
|
10.547 - 10.674 |
10.674 - 10.769 |
|
Technical analysis |
as of: 2021-03-03 4:40:15 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 19.96 One year: 24.61 |
| Support: |
Support1: 10.64 Support2: 8.85 |
| Resistance: |
Resistance1: 17.09 Resistance2: 21.07 |
| Pivot: |
12.84 |
| Moving Average: |
MA(5): 11.56 MA(20): 14.60
MA(100): 19.79 MA(250): 15.62  |
| MACD: |
MACD(12,26): -2.42 Signal(9): -2.33 |
| Stochastic oscillator: |
%K(14,3): 2.17 %D(3): 5.00 |
| RSI: |
RSI(14): 19.70 |
| 52-week: |
High: 25.39 Low: 6.25 Change(%): 7.8 |
| Average Vol(K): |
3-Month: 398218 10-Days: 531310 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.FOLD has closed above bottom band by 28.3%. Bollinger Bands are 101.8% wider than normal. The large width of the bands suggest high volatility as compared to FOLD's normal range. The bands have been in this wide range for 12 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Wed, 03 Mar 2021
Amicus Therapeutics' (FOLD) Buy Rating Reiterated at Robert W. Baird - MarketBeat
Tue, 02 Mar 2021
Amicus Therapeutics Inc (FOLD) Q4 2020 Earnings Call Transcript - Motley Fool
Mon, 01 Mar 2021
Amicus Therapeutics' (FOLD) CEO John Crowley on Q4 2020 Results - Earnings Call Transcript - Seeking Alpha
Mon, 01 Mar 2021
Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
Mon, 01 Mar 2021
Amicus Therapeutics: Q4 Earnings Insights - Yahoo Finance
Mon, 01 Mar 2021
Amicus Therapeutics Announces Full-Year 2020 Financial Results and Corporate Updates - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
 |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
261 |
| Shares Float (M) |
210 |
|
% Held by Insiders
|
0.56 |
|
% Held by Institutions
|
108.02 |
|
Shares Short (K)
|
27,250 |
|
Shares Short P. Month (K)
|
33,120 |
Stock Financials |
|
EPS
|
-1.150 |
|
EPS Est This Year
|
-1.320 |
|
EPS Est Next Year
|
-1.020 |
|
Book Value (p.s.)
|
1.230 |
|
Profit Margin
|
-120.18 |
|
Operating Margin
|
-109.06 |
|
Return on Assets (ttm)
|
-18.8 |
|
Return on Equity (ttm)
|
-68.0 |
|
Qtrly Rev. Growth
|
38.3 |
|
Gross Profit (p.s.)
|
0.615 |
|
Sales Per Share
|
0.943 |
|
EBITDA (p.s.)
|
-0.977 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-241 |
|
Levered Free Cash Flow (M)
|
-123 |
Stock Valuations |
|
PE Ratio
|
-9.27 |
|
PEG Ratio
|
|
|
Price to Book value
|
8.67 |
|
Price to Sales
|
11.31 |
|
Price to Cash Flow
|
-11.51 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
